Familial Mediterranean fever (FMF) is a hereditary disease characterised by recurrent episodes of fever, peritonitis, pleuritis, arthritis or erysipelas-like skin lesions. The disease affects mainly Jews, Armenians, Arabs, and Turks. Typically, the episodes last two to three days and resolve spontaneously.1 One of the main complications of FMF is the development of secondary amyloidosis (AA type). The kidneys are the main target organ involved, leading to chronic renal failure.

Colchicine has been the preferred treatment for FMF since 1972.2 It is effective in suppressing the episodes in more than 90% of the patients and prevents both the development of amyloidosis and the additional deterioration of renal functions in those with early amyloidosis.3 Colchicine exerts its main effect at the cellular level by its interaction with tubulin at the microtubules, inhibiting motility and exostosis of intracellular granules.4 Furthermore, it has also a powerful antimitotic effect by causing metaphase arrest and is capable of arresting meiosis.5 Therefore, in cases of infertility in patients treated with colchicine, it has been …